Differential diagnostic value of CD5 and CD117 expression in thoracic tumors: a large scale study of 1465 non-small cell lung cancer cases.
Differential diagnostic value of CD5 and CD117 expression in thoracic tumors: a large scale study of 1465 non-small cell lung cancer cases.
复制标题
CD5和CD117表达在胸部肿瘤中的差异诊断值：1465个非小细胞肺癌病例的大规模研究。
DOI：
10.1186/s13000-015-0441-7
复制
发表时间：
2015-12-08
影响因子：
2.6
通讯作者：
Warth A
中科院分区：
文献类型：
--
作者：
Kriegsmann M;Muley T;Harms A;Tavernar L;Goldmann T;Dienemann H;Herpel E;Warth A
胸部病理学家经常面对胸内/纵隔肿瘤的组织标本。特别是胸腺和肺鳞状细胞癌（SqCC）的鉴别是具有挑战性的。为了明确CD5和CD117在这种情况下的鉴别诊断价值，我们在1465例非小细胞肺癌（NSCLC）病例中对这两种标志物进行了大规模的表达研究。对1465例非小细胞肺癌福尔马林固定石蜡包埋切除标本的组织微阵列进行CD117和CD5抗体染色。两种标志物的阳性与临床病理变量相关。1457例可评估病例中有145例CD117阳性（9.9%），1427例可评估病例中有133例CD5阳性（9.3%）。CD117和CD5共表达28例（1.9%）。145例CD117阳性患者中，腺癌（ADC） 97例（66.8%），SqCC 34例（23.4%），腺鳞癌（ADSqCC） 5例（3.4%），大细胞癌（LC） 8例（5.5%），多形性癌（PC） 1例（0.6%）。CD5阳性组133例，ADC 123例（92.4%），SqCC 0例（0%），ADSqCC 4例（3.0%），LC 3例（2.2%），PC 3例（2.2%）。586例SqCC均未表达CD5。未观察到CD117-或CD5阳性与患者年龄、病理分期或T-、N-或M-类型相关。相当一部分非小细胞肺癌表现出CD117和CD5的阳性。由于CD5在肺部SqCC中未见表达，但在大多数胸腺鳞状细胞癌中均有表达，因此该免疫标志物的应用是鉴别胸部肿瘤的重要工具。本文的在线版本（doi:10.1186/s13000-015-0441-7）包含补充材料，可供授权用户使用。
Thoracic pathologists are frequently faced with tissue specimens from intrathoracic/mediastinal tumors. Specifically the differentiation between thymic and pulmonary squamous cell carcinomas (SqCC) can be challenging. In order to clarify the differential diagnostic value of CD5 and CD117 in this setting, we performed a large scale expression study of both markers in 1465 non-small cell lung cancer (NSCLC) cases. Tissue microarrays of formalin-fixed paraffin-embedded resection specimens of 1465 NSCLC were stained with antibodies against CD117 and CD5. Positivity of both markers was correlated with clinicopathological variables. CD117 was positive in 145 out of 1457 evaluable cases (9.9 %) and CD5 was positive in 133 out of 1427 evaluable cases (9.3 %). 28 cases (1.9 %) showed coexpression of CD117 and CD5. Among the 145 cases that were positive for CD117, 97 (66.8 %) were adenocarcinomas (ADC), 34 (23.4 %) were SqCC, 5 (3.4 %) were adenosquamous carcinomas (ADSqCC), 8 (5.5 %) were large cell carcinomas (LC), and one (0.6 %) was a pleomorphic carcinoma (PC). In the CD5 positive group consisting of 133 cases, 123 (92.4 %) were ADC, 0 (0 %) were SqCC, 4 (3.0 %) were ADSqCC, 3 (2.2 %) LC and 3 (2.2 %) were PC. None of the 586 SqCC showed expression of CD5. No association of CD117- or CD5 positivity to patients’ age, pathological stages or to T-, N-, or M- categories was observed. A substantial subset of NSCLC exhibit positivity of CD117 and CD5. Since CD5 expression was not observed in pulmonary SqCC, but is expressed in the majority of thymic squamous cell carcinomas, the application of this immunomarker is a valuable tool in the differential diagnosis of thoracic neoplasms. The online version of this article (doi:10.1186/s13000-015-0441-7) contains supplementary material, which is available to authorized users.